Lundbeck collaborates with CHDI on new Huntington's compound
This article was originally published in Scrip
Executive Summary
Lundbeck and CHDI Foundation have entered a research collaboration to investigate a targeted therapy for Huntington's disease (HD). CHDI will conduct preclinical studies on a compound discovered internally by Lundbeck. Research will focus on the compound's effect on P2X receptors that may be involved in HD.